Amber Therapeutics is a medical technology company focused on developing intelligent bioelectrical therapies for disorders of the peripheral nervous system. Many of these conditions lack long-term treatment options that are both effective and well tolerated. Founded in 2021 as a spinout from the University of Oxford, the company was established to translate neuro-engineering research into clinically viable medical devices. Backed by investors including Oxford Science Enterprises and 8VC, Amber has secured more than $100 million to fund product development and clinical evaluation.

The company’s work centers on implantable systems that can both stimulate and sense physiological activity. This feedback-driven capability distinguishes its technology from conventional neuromodulation devices that rely on fixed stimulation settings. By integrating sensing with stimulation, Amber’s systems are designed to adjust therapy delivery according to a patient’s biological signals. The company’s first product candidate focuses on mixed urinary incontinence, a condition that affects millions of people worldwide and often proves difficult to manage with existing therapies.

Building Adaptive, Closed-Loop Therapies

Amber Therapeutics develops closed-loop implantable systems that monitor physiological signals and modify stimulation in response to those signals. Traditional neuromodulation therapies typically deliver preset electrical patterns that do not change unless manually reprogrammed. In contrast, Amber’s platform is designed to interpret incoming biological data and adjust stimulation parameters in real time.

This design has particular relevance for mixed urinary incontinence, where nerve and muscle responses vary depending on posture, activity and individual neurological characteristics. Fixed stimulation schedules may not account for these fluctuations, which can limit treatment effectiveness. By sensing relevant physiological markers and adapting therapy delivery accordingly, Amber seeks to align treatment more closely with the body’s natural patterns.

Developing such systems requires coordination between hardware engineering, embedded software and clinical insight. Algorithms must accurately interpret signals while maintaining safety margins, and implantable components must meet rigorous durability and biocompatibility standards. Careful integration of these elements supports the goal of delivering responsive therapy that remains reliable over extended periods of use.

Targeting Conditions with Limited Options

Peripheral nerve disorders can disrupt essential bodily functions and reduce quality of life. Mixed urinary incontinence illustrates this challenge, as it includes both stress and urge symptoms that arise from different physiological mechanisms. Because multiple pathways may be involved, single-modality treatments often fail to provide sustained relief.

Current treatment options include medication, pelvic floor therapy and surgical procedures. While some patients benefit, others experience incomplete symptom control or side effects that limit long-term use. Amber’s bioelectrical therapy platform seeks to directly influence the nerve circuits involved in bladder regulation while simultaneously sensing responses relevant to symptom control.

Patients living with urinary incontinence frequently face physical discomfort as well as social and emotional strain. A therapy that adjusts to individual biological signals may offer an alternative for those who have not achieved satisfactory results with standard interventions. Although clinical validation remains essential, the technology is designed with this unmet need in mind.

Beyond urinary incontinence, the platform concept may extend to other peripheral nerve disorders where electrical signaling governs function. Any expansion into additional indications would depend on clinical evidence and regulatory review, but the underlying system is intended to be adaptable across related conditions.

From Research to Clinical Validation

Translating neuromodulation research into approved medical devices requires structured development and regulatory compliance. Amber is progressing through preclinical studies and clinical development stages to evaluate safety, device performance and therapeutic effectiveness. These evaluations involve systematic testing, data analysis and iterative refinement of device parameters.

Clinical trials are designed to assess whether adaptive stimulation provides measurable symptom relief while maintaining acceptable safety profiles. Investigators monitor patient outcomes, device behavior and potential adverse events to determine overall benefit. Data gathered during these stages inform design adjustments and regulatory submissions.

Medical device development often involves extended timelines due to stringent safety and performance requirements. Implantable systems must meet standards related to electrical safety, materials compatibility and long-term reliability. Funding secured by Amber supports these activities, including manufacturing scale-up and regulatory preparation.

Collaboration between engineers, clinicians and regulatory specialists supports progression from laboratory research to clinical application. Each stage builds upon prior validation to ensure that the therapy performs as intended within real-world medical settings.

Toward Responsive Bioelectrical Medicine

Technologies capable of sensing and reacting to physiological signals represent a significant development within modern medical engineering. Amber Therapeutics contributes to this field by integrating adaptive control into implantable neuromodulation systems. Rather than relying solely on static stimulation parameters, the company’s platform is designed to respond dynamically to biological input.

If clinical trials demonstrate safety and effectiveness, such systems could expand treatment options for patients with mixed urinary incontinence and potentially other nerve-related conditions. By interacting directly with the body’s electrical signaling pathways and adjusting therapy delivery in real time, adaptive bioelectrical devices seek to restore function in a manner that reflects individual physiological variation.

Amber Therapeutics’ work illustrates how neuro-engineering research can be translated into implantable medical technologies intended for clinical use. Through the development of sensing-enabled stimulation systems, the company is working to provide new therapeutic possibilities for patients living with peripheral nerve disorders that remain difficult to treat with existing modalities.

Aidan Crawley, Co-Founder & CEO, Amber Therapeutics